We are live on
!
Find out more
IMUC
ImmunoCellular Therapeutics, Ltd.
IMUC
IMUC
Delisted
IMUC was delisted on the 16th of October, 2018.
37 hedge funds and large institutions have $8.67M invested in ImmunoCellular Therapeutics, Ltd. in 2013 Q3 according to their latest regulatory filings, with 8 funds opening new positions, 3 increasing their positions, 14 reducing their positions, and 19 closing their positions.
New
Increased
Maintained
Reduced
Closed
14% less capital invested
Capital invested by funds: $10.1M → $8.67M (-$1.46M)
24% less funds holding
Funds holding: 49 → 37 (-12)
58% less first-time investments, than exits
New positions opened: 8 | Existing positions closed: 19
71% less call options, than puts
Call options by funds: $724K | Put options by funds: $2.52M
79% less repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 14
Holders
37
Holders Change
-12
Holders Change %
-24.49%
% of All Funds
1.2%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
8
Increased
3
Reduced
14
Closed
19
Calls
$724K
Puts
$2.52M
Net Calls
-$1.8M
Net Calls Change
-$2.1M
Top Buyers
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$834K |
| 2 |
HCM
Highbridge Capital Management
New York
|
+$340K |
| 3 |
Group One Trading
Chicago,
Illinois
|
+$299K |
| 4 |
BG
BlackRock Group
London,
United Kingdom
|
+$98.2K |
| 5 |
IFS
Ifrah Financial Services
Little Rock,
Arkansas
|
+$78.3K |
Top Sellers
| 1 |
Northern Trust
Chicago,
Illinois
|
-$1.15M |
| 2 |
Goldman Sachs
New York
|
-$688K |
| 3 |
Barclays
London,
United Kingdom
|
-$453K |
| 4 |
PP
Paloma Partners
Greenwich,
Connecticut
|
-$427K |
| 5 |
CS
Credit Suisse
Zurich,
Switzerland
|
-$422K |
